For primary central nervous system lymphoma (PCNSL), high-dose methotrexate (HD-MTX)-based chemotherapy remains a widely accepted induction therapy of newly diagnosed PCNSL in fit patients [1]. Despite significant advances in the treatment of PCNSL, such as cytarabine plus HD-MTX, and MATRix [2], these regimens had modest responses and a high risk of toxicities. No one regimen has been accepted as the optimal therapy. Bruton's tyrosine kinase inhibitor (BTKi)-based targeted immunochemotherapy has been recently investigated or under investigation [3, 4]; however, definite benefits are pending full results. The life-threatening toxicities (e.g., aspergillosis) with ibrutinib also limited its clinical application [5], motivating steps toward less toxic options. Orelabrutinib is an approved, second-generation BTKi with improved selectivity and persistent occupancy for BTK target, less off-target inhibition and notable blood-brain barrier permeability [6]. Previous studies have already reported encouraging signals of orelabrutinib combination in PCNSL [7]. Here, we reported the results of a prospective, multicenter, investigator-initiated, phase II study (NCT05549284) investigating the rituximab, HD-MTX plus orelabrutinib (RMO) regimen for newly diagnosed PCNSL. We enrolled patients aged 18-75 years with newly diagnosed PCNSL, no previous treatment, and ≥1 measurable lesion. Eligible patients received induction therapy with rituximab (intravenously 375 mg/m 2 on day (1), methotrexate (intravenously 3.5 g/m 2 on day (2), plus orelabrutinib (orally 150 mg once daily) every 3 weeks. Responders after the four cycles of RMO induction proceeded to protocol-specified consolidation or maintenance therapy according to tolerability and personal choice. Details on study design of this study are in Supplementary Methods. The primary endpoint was the overall response rate (ORR; complete response [CR] plus partial response [PR]) at the end of